ArticleFrontiers in medicine2022

Cardiovascular Protective Effects of Oral Hypoxia Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat in the Treatment of Type 4 Cardiorenal-Anemia Syndrome: Protocol of a Randomized Controlled Trial.

Yumin Wen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.